Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2017/11/010429
CTRI/2017/11/010429
Recruiting
Phase 3

Autologous Transfusion of Mobilized Peripheral Blood CD 34Positive Cells in Patients with Liver Cirrhosis

Asian Healthcare Foundation0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Asian Healthcare Foundation
Status
Recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Asian Healthcare Foundation

Eligibility Criteria

Inclusion Criteria

  • •1\.Age between 20\- 70 years
  • •2\.Clinically diagnosed for hepatic cirrhosis having a Child Pugh score of B or C
  • •3\.Not willing for immediate liver transplantation either due to lack of donor tissue or financial issues
  • •4\.Life expectancy of at least 3 months based on MELD score and Child Pugh Score
  • •5\.Ability to give informed consent

Exclusion Criteria

  • •1\.Age less than 20 or more than 70 years
  • •2\.Have liver tumors or history of any other cancer
  • •3\.Pregnant or lactating women
  • •4\.Patients with hepato renal syndrome and acute kidney injury ( Any creatinine \> 2 will be excluded)
  • •5\.Evidence of ongoing sepsis â?? as per Surviving sepsis guideline
  • •6\.Recent gastrointestinal bleeding or spontaneous bacterial peritonitis (within last one month)
  • •7\.Any HIV positive patients
  • •8\.Comorbid conditions such as severe cardiac and/or pulmonary disease
  • •9\.Inability to give informed consent.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Terminated
Not Applicable
Application of autologous peripheral blood-derived stem cell/progenitor cell (CD34+) + stem cells and hyperbaric oxygen therapy for patients with severe limb ischemia
ISRCTN80181257Ministry of Science and Technology (Taiwan)40
Completed
Not Applicable
Autologous peripheral blood stem cell transplantation using Thiotepa, Carboplatin and Etoposide conditioning in patients with relapsed or refractory Medulloblastoma, Primitive neuroectodermal tumor (PNET) and Atypical teratoma and rhabdoid tumor (ATRT)relapsed or refractory Medulloblastoma, Primitive neuroectodermal tumor (PNET) and Atypical teratoma and rhabdoid tumor (ATRT)
JPRN-UMIN000026084agoya University Graduate School of Medicine10
Completed
Not Applicable
Autologous peripheral blood stem cell transplantation as consolidation for high risk diffuse large B-cell lymphoma:A phase II studyDiffuse Large B-Cell Lymphoma:IPI high risk group, CR1
JPRN-UMIN000012546ishiwaki Municipal Hospital18
Recruiting
Not Applicable
Autologous peripheral blood stem cell transplantation for elderly patients (65-74 years old) with multiple myeloma.multiple myeloma
JPRN-UMIN000038905Tokyo-Kita Medical Center20
Completed
Phase 2
Autologous peripheral blood stem cell transplantation using MEAM regimen with HAART for refractory and relapsed HIV associated lymphoma: multicentered phase2 clinical trialRefractory and relapsed HIV associated lymphoma
JPRN-UMIN000003159Research fund of Ministry Health, Labour and Welfare for a counter measure against AIDS, Okada group and Tanabe group18